Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey
Pediatric Pulmonology · 2026-08 · 61 (8)
DOI: 10.1002/ppul.71778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 06.08.2026. Verfasst von Charissa W Kam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Cystic Fibrosis, Indoles, Benzodioxoles. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved lung function and the clinical course of people with cystic fibrosis (PwCF) but also can cause elevations in liver function tests (LFTs). While the prescribing information (PI) provides some recommendations for holding ETI or hepatically adjusting doses based on certain criteria, clinicians are often faced with clinical scenarios that do not meet those criteria (e.g. PwCF with CF liver disease [CFLD, now termed CF hepatobiliary involvement (CFHBI)] that do not meet Child‐Pugh Class B or C criteria). The purpose of this survey was to describe clinical practices regarding LFT monitoring and ETI dose adjustments in relation to hepatotoxicity and LFT abnormalities in PwCF with and without baseline CFLD or elevations in LFTs across adult and pediatric CF Foundation accredited care centers and affiliate programs (CFF‐ACCAP) in the United States.
Results
There were 53 unique respondents with representation from physicians, pharmacists, and advanced practitioners. When managing ETI in response to transaminase elevations that didn't meet PI recommendations for holding ETI in PwCF without CFLD or baseline LFT elevations, 51% of respondents would not change ETI therapy, and 41% would repeat LFTs, usually within a 2−4 week time frame. For those who met PI recommendations for pausing ETI, 49% of respondents would repeat LFTs in 1 month. In PwCF with baseline CFLD that doesn't meet Child‐Pugh Class B or C criteria or baseline LFT elevations, 74% of respondents initiated ETI at full dose, and 79% of respondents checked LFTs earlier than the PI recommendations.
Conclusion
Despite ETI's remarkable impact on pulmonary and extrapulmonary CF manifestations, the CF care team faces clinical challenges related to hepatotoxicity as well as appropriate monitoring and dosing of ETI in clinically gray scenarios. The results of this survey demonstrate the need for a multidisciplinary guideline to navigate these complex situations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.
- Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Pharmacotherapy and Pharmacy Services, University Health, San Antonio, Texas, USA.
- Department of Pharmacy, Texas Children's Hospital, Houston, Texas, USA.
- St. Louis Children's Hospital, St. Louis, Missouri, USA.
- Department of Pharmacy, University of Utah Hospitals and Clinics, Salt Lake City, Utah, USA.
ORCID-Profile: Charissa W Kam, Sabrina Garcia, Cameron J McKinzie
Zitieren
APA
Kam, C. W., Bullington, W., Elliott, A., Faircloth, J. M., Huntman, J., Jacobs, H. R., Poisson, M. O., Garcia, S., Witte, J., & McKinzie, C. J. (2026). Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey. Pediatric Pulmonology, 61(8). https://doi.org/10.1002/ppul.71778
Vancouver
Kam CW, Bullington W, Elliott A, Faircloth JM, Huntman J, Jacobs HR, et al. Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey. Pediatric Pulmonology. 2026;61(8). doi:10.1002/ppul.71778
BibTeX
@article{Kam2026,
author = {Kam, Charissa W and Bullington, Wendy and Elliott, Amber and Faircloth, Jenna M and Huntman, Jonica and Jacobs, HollyAnn R and Poisson, Margaret O and Garcia, Sabrina and Witte, Jennifer and McKinzie, Cameron J},
title = {Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {8},
doi = {10.1002/ppul.71778}
}
EUVIMED